LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Начало・Списък с акции・Amgen Inc

Amgen Inc

Затворен

СекторЗдравеопазване

326.2 -3.03

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

325.13

Максимум

336.3

Ключови измерители
By Trading Economics
Приходи	486M 1.8B
Продажби	-1.3B 8.6B
P/E Средно за сектора	22.936 51.415
EPS	5.15
Дивидентна доходност	2.91
Марж на печалбата	21.107
Служители	31,500
EBITDA	-2.3B 2.7B

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+8.47% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	2.91% 2.34%
Следващи печалби	4.08.2026 г.
Следваща дата на дивидент	5.06.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-5.4B 178B
Предишно отваряне	329.23
Предишно затваряне	326.2

Настроения в новините

By Acuity

32%

68%

81 / 345 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

270.44 / 276.44 Подкрепа & съпротива

Amgen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

30.04.2026 г., 20:16 ч. UTC

Печалби

Amgen Posts Higher 1Q Profit, Revenue

6.04.2026 г., 17:09 ч. UTC

Значими двигатели на пазара

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

3.02.2026 г., 21:49 ч. UTC

Печалби

Amgen Logs Higher 4Q Revenue on Double-Digit Volume Boost

6.01.2026 г., 15:14 ч. UTC

Придобивния, сливания и поглъщания

Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million

19.11.2025 г., 21:55 ч. UTC

Значими двигатели на пазара

Amgen Lung Cancer Drug Gets Full Approval From FDA

30.04.2026 г., 20:01 ч. UTC

Печалби

Amgen Sees FY26 EPS $15.62-EPS $17.10 >AMGN

30.04.2026 г., 20:01 ч. UTC

Печалби

Amgen 1Q Worldwide Prolia Sales $727M >AMGN

30.04.2026 г., 20:01 ч. UTC

Печалби

Amgen Sees FY26 Rev $37.1B-$38.5B >AMGN

30.04.2026 г., 20:01 ч. UTC

Печалби

Amgen Sees FY26 Adj EPS $21.70-Adj EPS $23.10 >AMGN

30.04.2026 г., 20:01 ч. UTC

Печалби

Amgen 1Q Adj EPS $5.15 >AMGN

30.04.2026 г., 20:01 ч. UTC

Печалби

Amgen 1Q Rev $8.62B >AMGN

30.04.2026 г., 20:01 ч. UTC

Печалби

Amgen 1Q Net $1.82B >AMGN

30.04.2026 г., 20:01 ч. UTC

Печалби

Amgen 1Q EPS $3.34 >AMGN

1.04.2026 г., 20:07 ч. UTC

Придобивния, сливания и поглъщания

Why 2026 Is Biotech's Comeback Year -- Barrons.com

4.02.2026 г., 19:56 ч. UTC

Пазарно говорене

Amgen's Strong Core Growth Offsets Wait for Weightloss Drug -- Market Talk

3.02.2026 г., 21:01 ч. UTC

Печалби

Amgen 4Q Worldwide XGEVA Sales $447M >AMGN

3.02.2026 г., 21:01 ч. UTC

Печалби

Amgen 4Q Worldwide Enbrel Sales $532M >AMGN

3.02.2026 г., 21:01 ч. UTC

Печалби

Amgen 4Q Adj EPS $5.29 >AMGN

3.02.2026 г., 21:01 ч. UTC

Печалби

Amgen 4Q Net $1.33B >AMGN

3.02.2026 г., 21:01 ч. UTC

Печалби

Amgen 4Q Worldwide Prolia Sales $1.05B >AMGN

3.02.2026 г., 21:01 ч. UTC

Печалби

Amgen 4Q Rev $9.9B >AMGN

3.02.2026 г., 21:01 ч. UTC

Печалби

Amgen Sees FY Adj EPS $21.60-Adj EPS $23.00 >AMGN

3.02.2026 г., 21:01 ч. UTC

Печалби

Amgen 4Q Worldwide Neulasta Sales $132M >AMGN

3.02.2026 г., 21:01 ч. UTC

Печалби

Amgen Sees FY Rev $37B-$38.4B >AMGN

3.02.2026 г., 21:01 ч. UTC

Печалби

Amgen Sees FY EPS $15.45-EPS $16.94 >AMGN

3.02.2026 г., 21:01 ч. UTC

Печалби

Amgen 4Q EPS $2.45 >AMGN

28.01.2026 г., 17:47 ч. UTC

Печалби

Pharma Stocks Are Close to 'Breaking Out.' Earnings Could Set Them Free. -- Barrons.com

6.01.2026 г., 14:01 ч. UTC

Придобивния, сливания и поглъщания

Amgen: Deal Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia >AMGN

6.01.2026 г., 14:01 ч. UTC

Придобивния, сливания и поглъщания

Amgen Acquires Dark Blue Therapeutics in Transaction Valued at Up to $840 Million >AMGN

6.01.2026 г., 14:00 ч. UTC

Придобивния, сливания и поглъщания

AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE >AMGN

Сравнение с други в отрасъла

Ценова промяна

Amgen Inc Прогноза

Ценова цел

By TipRanks

8.47% нагоре

12-месечна прогноза

Среден 364.7 USD 8.47%

Висок 427 USD

Нисък 300 USD

Според 24 анализатори от Wall Street, предложили 12-месечна ценова цел за Amgen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

24 ratings

Купи

Задържане

Продай

Според 24 анализатори, дали борсови рейтинги на Amgen Inc през последните 3 месеца.

Техническа оценка

By Trading Central

270.44 / 276.44Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Настроение

By Acuity

81 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.